Seed Financing Supports the Transition Toward Clinical Development.
In 2019, Odimma Therapeutics secured €2 million in seed funding, combining a €1 million investment led by Cap Innov’Est with €1 million in support from Bpifrance’s Deeptech program.
The financing marked a major milestone in the company’s development, providing the resources needed to advance its proprietary personalized cancer immunotherapy platform toward its first clinical trial.
The funding supports key regulatory, pharmaceutical and manufacturing activities while accelerating research and development of ODI-2001, Odimma’s next-generation immunotherapy designed to harness the patient’s own immune system against tumor-specific neoantigens.
The investment also represented strong validation from both private investors and France’s public innovation ecosystem, recognizing the scientific potential of Odimma’s platform and its ambition to transform precision oncology through personalized immunotherapy.
